<div id="readability-page-1"><div><p>Health-care companies rose as traders bought into the defensive sector ahead of key economic and inflation data.</p><p>    Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on the drug would be delayed again. </p><p>    Obesity-drug maker Eli Lilly shares rose by more than 3%, testing all-time highs, amid optimism about demand. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-15-25 1753ET</p></div></div>

礼来

赛诺菲

赛诺菲集团

<p>医疗保健公司股价上涨，因为交易者在关键经济和通胀数据公布前买入防御性行业。赛诺菲的股价下跌，因为其一项针对多发性硬化症的实验性治疗遭遇双重挫折，晚期研究的结果未能达到关键目标，美国监管机构表示该药物的决定将再次推迟。肥胖药物制造商礼来的股价上涨超过 3%，测试历史新高，市场对需求的乐观情绪推动了股价。请联系 Rob Curran，邮箱为 rob.curran@dowjones.com (完) 道琼斯新闻社 12-15-25 1753ET</p>

由于防御性偏好，医疗保健板块上涨——医疗保健综述